Institute of Pharmacology and Clinical Pharmacology
Department provides teaching of subjects: Pharmacology and Clinical Pharmacology
Teaching of Pharmacology is oriented to gain basic information about drugs and ways of their rational usage. It is realised by Problem Based Learning (PBL). During seminars are studied cases of patients with selected diseases and students work out pharmacotherapeutic plan. Result of case analysis is drug selection on the basis of these criterias: efficacy, safety, suitability and costs. Part of tutorials is to prepare and present seminary essays on selected topics.
Scientific Research Activity
Within the basic research our department is focused on Cardiovascular Pharmacology. Research activity involves evaluation of effects of vasoactive substances on vascular reactivity in different endothelial dysfunction models, respectively damage of the endothelium, evaluation of endothelium-protective properties of drugs and endothelial markers quantification. In cooperation with clinics, endothelial dysfunction markers are evaluated in patients with high cardiovascular risk.
In Clinical Pharmacology the department is focused on analysis of drug utilization with aspect to drug safety, risk perception and pharmacoeconomic evaluation of treatment. In pharmacoepidemiologic studies is evaluated quality of pharmacotherapy in risk group of population (children, elderly) with using quality indicators.
List of the most important scientific publications:
Wawruch M, Murin J, Tesar T, Petrova M, Paduchova M, Celovska D, Havelkova B, Trnka M, Masarykova L, Alfian SD, Aarnio E. Reinitiation and Subsequent Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among New and Prevalent Users Aged 65 Years or More with Peripheral Arterial Disease. Biomedicines. 2023 Jan 26;11(2):368. doi: 10.3390/biomedicines11020368.
Lassanova M, Lassan S, Liskova S, Tesar T and Cicova M. Analysis of spontaneous reports of suspected adverse reactions after vaccination against COVID19 in Slovakia. Front. Pharmacol. 2023; 14:1097890. doi: 10.3389/fphar.2023.1097890.
Wawruch M, Murin J, Tesar T, Paduchova M, Petrova M, Celovska D, Havelkova B, Trnka M, Masarykova L, Alfian SD, Aarnio E. Gender Differences in Non-Persistence with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among Older Hypertensive Patients with Peripheral Arterial Disease. Biomedicines. 2022; 10 (7):1479. doi: 10.3390/biomedicines10071479.
Laššánová M, Laššán Š, Tisoňová J, Čičová M. Risk Perception of Treatment and Prevention of Covid-19 Disease in Slovakia. European Pharmaceutical Journal. 2022; 69(S1): 16-16 [online]. ISSN (print) 2453-6725.
Laššán Š, Keszegh J, Laššánová M. Characteristics of COPD patients treated with single-inhaler triple therapy in real-life clinical practice. Bratislava medical journal. 2022; 123(1): 27-36. ISSN (print) 0006-9248.
Líšková S. The organ-specific nitric oxide synthase activity in the interaction with sympathetic nerve activity: a hypothesis. Physiological research. 2021; 70 (2): 169-175.
Bernatová I, Líšková S: Mechanisms modified by (-)-epicatechin and taxifolin relevant for the treatment of hypertension and viral infection: Knowledge from preclinical studies. Antioxidants. 2021; 10(3): 1-26. art. no. 467 [online].
Mičurová A, Kluknavský M, Líšková S, Bališ P, Škratek M, Okruhlicová M, Maňka J, Bernatová I. Differences in distribution and biological effects of f3o4@peg nanoparticles in normotensive and hypertensive rats - focus on vascular function and liver. Biomedicines. 2021; 9(12): 1-18. art. no. 1855.
Wawruch M, Murin J, Tesar T, Paduchova M, Petrova M, Celovska D, Matalova P, Havelkova B, Trnka M, Aarnio E. Adherence to Antiplatelet Medications among Persistent and Non-Persistent Older Patients with Peripheral Arterial Disease. Biomedicines. 2021; 9 (12): 1800. doi: 10.3390/biomedicines9121800. (IF(2020)=6,081) jcr – Q1
Wawruch M, Murin J, Tesar T, Paduchova M, Petrova M, Celovska D, Havelkova B, Trnka M, Aarnio E. Reinitiation and Subsequent Discontinuation of Antiplatelet Treatment in Nonpersistent Older Patients with Peripheral Arterial Disease. Biomedicines. 2021; 9 (9): 1280. doi: 10.3390/biomedicines9091280. (IF(2020)=6,081) jcr – Q1
Hrubisko M, Danis R, Huorka M, Wawruch M. Histamine Intolerance-The More We Know the Less We Know. A Review. Nutrients. 2021; 13 (7): 2228. doi: 10.3390/nu13072228. (IF(2020)=5,717)
Wawruch M, Murin J, Tesar T, Paduchova M, Petrova M, Celovska D, Havelkova B, Trnka M, Aarnio E. Non-Persistence With Antiplatelet Medications Among Older Patients With Peripheral Arterial Disease. Front Pharmacol. 2021; 12: 687549. doi: 10.3389/fphar.2021.687549. (IF(2020)=5,810) jcr – Q1
Laššánová M, Líšková S, Tisoňová J, Fundarková S, Laššán Š. Biopharmaceuticals safety perception safety perception in Slovakia: considerations and real-life pharmacovigilance data. Bratislava medical journal. 2021; 122(7): 443-448. ISSN (print) 0006-9248.
Wawruch M, Wimmer G Jr, Murin J, Paduchova M, Petrova M, Tesar T, Matalova P, Havelkova B, Trnka M, Aarnio E. Non-Adherence to Statin Treatment in Older Patients with Peripheral Arterial Disease Depending on Persistence Status. Biomedicines. 2020; 8 (10): 378. doi: 10.3390/biomedicines8100378. (IF(2020)=6,081) jcr – Q1
Wawruch M, Wimmer G Jr, Murin J, Paduchova M, Tesar T, Hlinkova L, Slavkovsky P, Aarnio E. Factors Associated with Reinitiation of Statin Treatment in Older Patients with Peripheral Arterial Disease. Drugs Aging 2020; 37 (8): 595-604. doi: 10.1007/s40266-020-00772-z (IF(2020)=3,923) jcr – Q2
Wawruch M, Wimmer G Jr, Murin J, Paduchova M, Tesar T, Hlinkova L, Slavkovsky P, Fabryova L, Aarnio E. Patient-Associated Characteristics Influencing the Risk for Non-Persistence with Statins in Older Patients with Peripheral Arterial Disease. Drugs Aging 2019; 36 (9): 863-873. doi: 10.1007/s40266-019-00689-2. (IF(2019)=2,824) jcr – Q2
De Vries TP, Daniels JM, Mulder CW, Groot OA, Wewerinke L, Barnes KI, Bakathir HA, Hassan NA, Van Bortel L, Kriska M, Santoso B, Sanz EJ, Thomas M, Ziganshina LE, Bezemer PD, Van Kan C, Richir MC, Hogerzeil HV. Should medical students learn to develop a personal formulary? An international, multicentre, randomised controlled study. Eur J Clin Pharmacol. 2008 Jun;64(6):641-6.
Wawruch M, Zikavska M, Wsolova L, Kuzelova M, Tisonova J, Gajdosik J, Urbanek K, Kristova V. Polypharmacy in elderly hospitalised patients in Slovakia. Pharm World Sci. 2008 Jun;30(3):235-42.
Kristova V, Kiss A, Pirnik Z, Kriska M, Jezova D. Effect of pentoxifylline on endothelaemia and hypothalamic-pituitary-adrenocortical axis activation in female rats under stress exposure. Gen Physiol Biophys 2006; 25 (1): 81-89.
Torok J, Liskova S, Kristova V. Effect of melatonin on neurogenic control of vascular tone. Homeostasis 2005; 43 (4): 184-187.
Tisoňová J, Szalayová A, Kriška M, Gibala P, Foltán V. Factors influencing the spontaneous reporting of adverse drug reactions - The experience of the Slovak Republic. Pharmacoepidemiol Drug Saf 2004; 13 (5): 333-337.
Dedík L, Ďurišová M, Svrček V, Vojtko R, Kristová V, Kriška M. Computer-based methods for measurement, recording and modeling vessel responses in vitro: A pilot study with noradrenaline. Met Find Exp Clin Pharmacol 2003; 25 (6): 441-445.
Grant Projects of the Department:
Study of endothelium-protective effects of drugs on the experimental models of endothelial damage. (Principal of the project: Assoc. prof. Viera Kristová, MD, PhD., Grant VEGA N°: 1/2293/05)
Perception of risk – key factor of their utilization. (Principal of the project: Prof. Milan Kriška, MD, DSc., Grant VEGA N°: 1/2292/05)
In cooperation with the Department of Experimental Endocrinology SAV: Neuroendocrinological mechanisms in relation to psychological condition and effect of drugs. (Principal of the project: Prof. PharmDr. Daniela Ježová, DSc., Grant VEGA N°: 2/5064/25)
In cooperation with the Department of Experimental Pharmacology SAV: Ischaemic-reperfusion damage in experimental diabetes type 2 and possibilities of its pharmacologic influence. (Principal of the project: RNDr. Ružena Sotníková, PhD., Grant VEGA N°: 2/5009/25)
In cooperation with Mechanical Engineering Faculty STU: New computer methods for analysis of fate and effect of biologically active substances. (Principal of the project: Assoc. prof. Ing. Ladislav Dedík, PhD., Grant VEGA N°: 1/0521/03)
- Consulting activity: Drug Information Centre
- Expertise activity
- Evaluation of medicaments within registration process
- Cooperation with Uppsala Monitoring Centre in programme focused on drug safety
Institute is training PhD. students in the study programme of
Our PhD. students:
MUDr. Vasil Hricák
PharmDr. Orsolya H r u b á
Mgr. Petra M a s s a r o v á
Mgr. Katarína V r a n e c o v á
Mgr. Lucia Ž i g o v á